The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions

Inclusion Criteria:

• Patient suffering from plaque psoriasis for more than a year with at least one active skin lesion> 4 cm2 in the photo-protected area.
• Patient using effective contraception (IUD, adapted pill, condom, etc.)
• The patient must have given their free and informed consent and signed the consent form
• The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

• Patient with another form or stage of psoriasis
• Patient on anti-cytokine treatment during the 6 months (180 days) before inclusion
• Patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3) methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) PUVA, (5) UVB, (6) vitamin D3 during the 4 weeks (28 days) before inclusion
• Patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days) before inclusion
• Patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple or high doses of NSAIDs, etc.); creatinine clearance less than 50 ml / min; serum phosphorus below 1.0 mg / dl (0.32 mmol / l).
• Patient with active viral infection (HBV, HCV and HIV), or uncontrolled acute infection.
• Patient with hypersensitivity to one of the active substances or to any of the excipients (non-medicinal ingredients).
• Patient with uncontrolled coagulation disorder, history of keloid scars
• Patient with an allergy to local anesthetics; any condition likely to interfere at the time of the pre-inclusion visit, with the evaluation of the main objective such as eczema, psychiatric disorders
• Patient with uncontrolled systemic parameters The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study